文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference.

作者信息

Llovet Josep M, Villanueva Augusto, Marrero Jorge A, Schwartz Myron, Meyer Tim, Galle Peter R, Lencioni Riccardo, Greten Tim F, Kudo Masatoshi, Mandrekar Sumithra J, Zhu Andrew X, Finn Richard S, Roberts Lewis R

机构信息

Mount Sinai Liver Cancer Program, Division of Liver Diseases, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY.

Translational Research in Hepatic Oncology, Liver Unit, IDIBAPS, Hospital Clinic, University of Barcelona, Barcelona, Spain.

出版信息

Hepatology. 2021 Jan;73 Suppl 1:158-191. doi: 10.1002/hep.31327. Epub 2020 Sep 9.

DOI:10.1002/hep.31327
PMID:32430997
Abstract
摘要

相似文献

[1]
Trial Design and Endpoints in Hepatocellular Carcinoma: AASLD Consensus Conference.

Hepatology. 2021-1

[2]
Major achievements in hepatocellular carcinoma.

Lancet. 2009-2-21

[3]
Perspectives on the Neoadjuvant Use of Immunotherapy in Hepatocellular Carcinoma.

Hepatology. 2021-7

[4]
Toripalimab Combined With Hepatic Arterial Infusion Chemotherapy Versus Lenvatinib for Advanced Hepatocellular Carcinoma.

Technol Cancer Res Treat. 2021

[5]
Nonoperative therapies for combined modality treatment of hepatocellular cancer: expert consensus conference.

HPB (Oxford). 2010-6

[6]
Comparative efficacy and safety of transarterial chemoembolization combined with tyrosine kinase inhibitors and immune checkpoint inhibitors versus tyrosine kinase inhibitors and immune checkpoint inhibitors alone in advanced hepatocellular carcinoma: a systematic review and meta-analysis.

World J Surg Oncol. 2025-4-7

[7]
Transarterial chemoembolization combined with tyrosine kinase inhibitors and/or immune checkpoint inhibitors induced hypothyroidism is associated with improved overall survival in hepatocellular carcinoma.

Cancer Immunol Immunother. 2025-5-24

[8]
Treatment of unresectable hepatocellular carcinoma.

N Engl J Med. 1995-9-28

[9]
Transarterial chemoembolization using doxorubicin beads for unresectable hepatocellular carcinoma.

Onkologie. 2010

[10]
Prognostic prediction and treatment strategy in hepatocellular carcinoma.

Hepatology. 2002-3

引用本文的文献

[1]
Role of immune checkpoint inhibitor combinations in resectable and unresectable, embolization-eligible hepatocellular carcinoma.

Ther Adv Med Oncol. 2025-7-24

[2]
Diagnostic performance comparisons of two commonly used multi-biomarker-based scores for detection of hepatocellular carcinoma in non-alcoholic fatty liver disease.

ILIVER. 2024-5-21

[3]
Liver function dynamics in advanced hepatocellular carcinoma receiving immune checkpoint inhibitors and anti-vascular endothelial growth factor antibody/tyrosine kinase inhibitors with or without transarterial chemoembolization.

Ther Adv Med Oncol. 2025-6-30

[4]
Role of novel immunotherapy combinations in the management of advanced-stage hepatocellular carcinoma.

Nat Rev Clin Oncol. 2025-6-30

[5]
The association between stage migration and overall survival after radiation-based therapies in patients with hepatocellular carcinoma.

JHEP Rep. 2025-5-7

[6]
Immunotherapy targeting liver cancer tumor-initiating cells: challenges, mechanisms, and emerging therapeutic horizons.

Front Immunol. 2025-6-11

[7]
Biomarker, efficacy and safety analysis of transcatheter arterial chemoembolization combined with atezolizumab and bevacizumab for unresectable hepatocellular carcinoma.

Cancer Immunol Immunother. 2025-5-19

[8]
Comprehensive treatment of intermediate and advanced primary hepatocellular carcinoma based on transcatheter arterial chemoembolization (Review).

Oncol Lett. 2025-5-7

[9]
Immunotherapy combined with targeted therapy and transcatheter arterial chemoembolization: a promising approach for advanced liver cancer.

Am J Transl Res. 2025-4-15

[10]
Systemic Therapy Combined with Locoregional Therapy in Intermediate-stage Hepatocellular Carcinoma.

Interv Radiol (Higashimatsuyama). 2024-12-13

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索